Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2006

01-06-2006 | Educational Review

Colorectal Cancer Screening and Surveillance: Current Standards and Future Trends

Authors: Steve R. Martinez, MD, Shawn E. Young, MD, Rebecca E. Hoedema, MD, Leland J. Foshag, MD, Anton J. Bilchik, MD, PhD

Published in: Annals of Surgical Oncology | Issue 6/2006

Login to get access

Abstract

Its prevalence, long premalignant course, and favorable response to early intervention make colorectal cancer an ideal target for screening regimens. The success of these regimens depends on accurate assessment of risk factors, patient compliance with scheduled visits and tests, and physician knowledge of screening strategies. We review the current recommendations for colorectal cancer screening in general and at-risk populations, comment on surveillance methods in high-risk patients, and examine current trends that will likely influence screening regimens in the future.
Literature
1.
Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10–30PubMed
2.
3.
Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348:1472–7CrossRefPubMed
4.
Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348:1467–71CrossRefPubMed
5.
Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328:1365–71CrossRefPubMed
6.
Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91:434–7CrossRefPubMed
7.
Smith RA, Cokkinides V, Eyre HJ. American cancer society guidelines for the early detection of cancer, 2005. CA Cancer J Clin 2005; 55:31–44PubMedCrossRef
8.
Collins JF, Lieberman DA, Durbin TE, Weiss DG. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005; 142:81–5PubMed
9.
Nadel MR, Shapiro JA, Klabunde CN, et al. A national survey of primary care physicians’ methods for screening for fecal occult blood. Ann Intern Med 2005; 142:86–94PubMed
10.
Mamazza J, Gordon PH. The changing distribution of large intestinal cancer. Dis Colon Rectum 1982; 25:558–62PubMed
11.
Vobecky J, Leduc C, Devroede G. Sex differences in the changing anatomic distribution of colorectal carcinoma. Cancer 1984; 54:3065–9PubMed
12.
Ghahremani GG, Dowlatshahi K. Colorectal carcinomas: diagnostic implications of their changing frequency and anatomic distribution. World J Surg 1989; 13:321–4CrossRefPubMed
13.
Cheng X, Chen VW, Steele B, et al. Subsite-specific incidence rate and stage of disease in colorectal cancer by race, gender, and age group in the United States, 1992-1997. Cancer 2001; 92:2547–54CrossRefPubMed
14.
Mensink PB, Kolkman JJ, Van Baarlen J, Kleibeuker JH. Change in anatomic distribution and incidence of colorectal carcinoma over a period of 15 years: clinical considerations. Dis Colon Rectum 2002; 45:1393–6CrossRefPubMed
15.
Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326:653–7PubMedCrossRef
16.
Muller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med 1995; 155:1741–8CrossRefPubMed
17.
Newcomb PA, Storer BE, Morimoto LM, Templeton A, Potter JD. Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst 2003; 95:622–5PubMedCrossRef
18.
Nelson DB, McQuaid KR, Bond JH, Lieberman DA, Weiss DG, Johnston TK. Procedural success and complications of large-scale screening colonoscopy. Gastrointest Endosc 2002; 55:307–14CrossRefPubMed
19.
Wexner SD, Garbus JE, Singh JJ. A prospective analysis of 13,580 colonoscopies. Reevaluation of credentialing guidelines. Surg Endosc 2001; 15:251–61CrossRefPubMed
20.
Fork FT. Double contrast enema and colonoscopy in polyp detection. Gut 1981; 22:971–7PubMed
21.
Rex DK, Weddle RA, Lehman GA, et al. Flexible sigmoidoscopy plus air contrast barium enema versus colonoscopy for suspected lower gastrointestinal bleeding. Gastroenterology 1990; 98:855–61PubMed
22.
Winawer SJ, Stewart ET, Zauber AG, et al. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. N Engl J Med 2000; 342:1766–72CrossRefPubMed
23.
Cotton PB, Durkalski VL, Pineau BC, et al. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA 2004; 291:1713–9CrossRefPubMed
24.
Macari M, Bini EJ, Jacobs SL, et al. Colorectal polyps and cancers in asymptomatic average-risk patients: evaluation with CT colonography. Radiology 2004; 230:629–36PubMed
25.
Pickhardt PJ, Choi JR, Hwang I, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003; 349:2191–200CrossRefPubMed
26.
Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256:102–5PubMed
27.
Villa E, Dugani A, Rebecchi AM, et al. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology 1996; 110:1346–53CrossRefPubMed
28.
Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001; 93:858–65CrossRefPubMed
29.
Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119:1219–27CrossRefPubMed
30.
Koshiji M, Yonekura Y, Saito T, Yoshioka K. Microsatellite analysis of fecal DNA for colorectal cancer detection. J Surg Oncol 2002; 80:34–40CrossRefPubMed
31.
Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351:2704–14CrossRefPubMed
32.
33.
Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RK. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989; 2:783–5CrossRefPubMed
34.
Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116:1453–6CrossRefPubMed
35.
Dunlop MG. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polyposis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut 2002; 51(Suppl 5):V21–7PubMedCrossRef
36.
Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997; 277:997–1003CrossRefPubMed
37.
Benson AB III, Desch CE, Flynn PJ, et al. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol 2000; 18:3586–8PubMed
38.
Law CH, Wright FC, Rapanos T, et al. Impact of lymph node retrieval and pathological ultra-staging on the prognosis of stage II colon cancer. J Surg Oncol 2003; 84:120–6CrossRefPubMed
39.
Tepper JE, O’Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001; 19:157–63PubMed
40.
Green FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002
41.
Sobin LH, Wittekind C, eds. International Union Against Cancer (UICC). TNM Classification of Malignant Tumors. 6th ed. New York: Wiley, 2002
42.
Prandi M, Lionetto R, Bini A, et al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 2002; 235:458–63CrossRefPubMed
43.
Meyerhardt JA, Mayer RJ. Follow-up strategies after curative resection of colorectal cancer. Semin Oncol 2003; 30:349–60CrossRefPubMed
44.
Grossmann EM, Johnson FE, Virgo KS, Longo WE, Fossati R. Follow-up of colorectal cancer patients after resection with curative intent-the GILDA trial. Surg Oncol 2004; 13:119–24CrossRefPubMed
45.
NCCN Cancer Panel Members. NCCN clinical practice guidelines in oncology. Colon Cancer 2004; 2:1–27
46.
Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer. J Clin Oncol 2004; 22:1564–71CrossRefPubMed
47.
Garrity MM, Burgart LJ, Mahoney MR, et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes’ B2 or C colon cancer: a North Central Cancer Treatment Group study. J Clin Oncol 2004; 22:1572–82CrossRefPubMed
48.
Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 2001; 1:104–9PubMedCrossRef
Metadata
Title
Colorectal Cancer Screening and Surveillance: Current Standards and Future Trends
Authors
Steve R. Martinez, MD
Shawn E. Young, MD
Rebecca E. Hoedema, MD
Leland J. Foshag, MD
Anton J. Bilchik, MD, PhD
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2006.03.087

Other articles of this Issue 6/2006

Annals of Surgical Oncology 6/2006 Go to the issue

OriginalPaper

Effect of Primary Tumor Extirpation in Breast Cancer Patients Who Present With Stage IV Disease and an Intact Primary Tumor

OriginalPaper

Improved Outcome of Resection of Hilar Cholangiocarcinoma (Klatskin Tumor)

Editorial

Patient Satisfaction: An Increasingly Important Measure of Quality

Review

Current Issues in Adjuvant Treatment of Stage II Colon Cancer

OriginalPaper

The Surgeon-Patient Interaction in Older Women With Breast Cancer: What Are the Determinants of a Helpful Discussion?

OriginalPaper

Fine-Needle Aspiration Optimizes Surgical Management in Patients With Thyroid Cancer